retatrutide triple agonist glp-1 gip glucagon receptors phase 2 nejm 2023 Retatrutide, a GIP, and receptor agonist, for people with type diabetes: a randomised, retatrutide triple agonist glp-1 gip
Pay in 4 interest-free payments of $6.04 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6





















